/

KPRX

Kiora Pharmaceuticals, Inc.Closed

2.47−0.09 −3.52%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delay

Open

2.55

Prev close

2.56

Day range

2.472.55

52-week range

1.772.91

Volume

2.87K0.17×

Mkt cap

10.93M

P/E ttm

—

Fwd P/E

-1.11

EPS ttm

-2.46

Div yield

0.00%

Earnings

—

From 52w high

−15.12%

Price Chart

Yahoo Finance · delayed

KPRXOct 13, 2026O 2.55H 2.55L 2.47C 2.47−0.09 (−3.52%)Vol 3.00K

SMA 502.59
SMA 2002.40

1Y change −8.52% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

KPRX Kiora Pharmaceuticals, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −1.20%
1 month: −6.79%
3 months: −0.40%
6 months: +1.23%
Year to date: +25.38%
1 year: −9.19%

Valuation & ownership

Market cap: 10.93M
Enterprise value: −788.37K
P/E (ttm): —
Forward P/E: -1.11
PEG ratio: —
Price / book: 0.93
Price / sales (ttm): —
EV / EBITDA: 0.08
EPS (ttm): -2.46
EPS (forward): -2.23
Beta (5y monthly): -0.21
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 4.42M
Float: 3.85M
Short % of float: 0.08%
Short ratio (days): 0.25
Held by insiders: 8.91%
Held by institutions: 36.35%
Avg volume (3m): 17.28K
50-day average: 2.59
200-day average: 2.40
52-week change: −9.19%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 39.9
vs 50-day SMA: −4.72%
vs 200-day SMA: +2.81%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 3.24%
Realised vol (20d, ann.): 31.5%
From 52-week high: −15.12%
From 52-week low: +39.94%

ANR

Analyst Consensus

1 analysts

Consensus

—

Mean target

12.00

+385.83% implied

Low 12.00Median 12.00High 12.00

Recommendation trend

Now1 / 0 / 0

Buy / hold / sell counts

Financial Snapshot

Full statements →trailing twelve months

DES

About Kiora Pharmaceuticals, Inc.

Yahoo Finance profile

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis. It has a strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 13
Headquarters: Encinitas, CA, United States
Website: kiorapharma.com
Officers: Dr. Brian M. Strem Ph.D. President, CEO & Director
Ms. Melissa Tosca CPA Chief Financial Officer

SEAS

Seasonality · KPRX

2015–2026 · monthly returns

Strongest month Feb +12.62%Weakest month Mar −15.49%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	21.8	-12.9	-7.7	21.8	14.0	-1.9	-2.7	-2.0	2.0	-3.5			+25.4%
2025	22.1	-19.4	-7.4	7.0	-7.5	-3.4	-9.7	6.9	0.0	-16.9	-14.3	-0.5	−40.3%
2024	5.7	21.6	5.2	-28.8	-2.0	-5.3	10.2	-20.1	-1.1	-1.1	-9.9	1.2	−29.8%
2023	2.9	26.1	-24.9	32.9	-52.9	-69.2	-7.3	-16.4	14.1	3.9	-12.4	1.0	−84.8%
2022	-49.0	-18.8	-0.5	-14.8	-17.0	7.0	-68.8	32.0	-20.7	6.8	-46.0	-3.4	−94.3%
2021	28.0	-12.2	-10.1	-15.1	3.8	-17.1	-30.8	-27.0	22.3	-15.6	-20.5	0.0	−69.4%
2020	-42.7	0.2	-9.6	0.2	-2.1	-5.7	-15.2	-0.5	-3.4	-10.2	-6.0	48.9	−50.8%
2019	4.3	-11.3	-29.1	-4.9	-13.4	-4.4	-13.7	-18.2	25.6	23.8	98.4	27.8	+43.7%
2018	-2.8	-45.2	-33.3	39.2	6.2	-5.7	0.6	5.1	-44.6	0.0	63.2	-8.1	−56.5%
2017	-6.0	73.5	-4.1	-23.1	-3.6	-27.5	-2.2	-26.1	18.2	-5.7	-2.1	-0.9	−34.4%
2016	-38.0	111.8	-14.4	13.6	7.1	-30.9	-22.0	-12.4	-2.8	-14.0	14.9	-4.1	−40.5%
2015			-42.1	7.1	20.0	11.1	43.0	-47.6	-24.0	-7.0	14.0	-9.3	−54.7%

INSD

Insider Activity · KPRX

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Mar 5, 2026	Strem Brian M.Chief Executive Officer	Stock Award(Grant) at price 0.00 per share.	16.7K	—
Mar 5, 2026	Daniels Eric JosephOfficer	Stock Award(Grant) at price 0.00 per share.	6.5K	—
Mar 5, 2026	Tosca MelissaChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	6.5K	—
Mar 31, 2025	Strem Brian M.Chief Executive Officer	Stock Award(Grant) at price 0.00 per share.	15.9K	—
Mar 31, 2025	Daniels Eric JosephOfficer	Stock Award(Grant) at price 0.00 per share.	7.8K	—
Mar 31, 2025	Tosca MelissaChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	7.8K	—

13F

Investors Holding KPRX

latest 13F filings of 29 followed managers

Investors holding KPRX
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$78.4K	0.00%	29.82K	New	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

KPRX

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

KPRX

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Kiora Pharmaceuticals, Inc.

Seasonality · KPRX

Insider Activity · KPRX

Congress Trades · KPRX

Investors Holding KPRX

Investors Holding KPRX

Congress Trades · KPRX

Insider Activity · KPRX

Seasonality · KPRX

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Kiora Pharmaceuticals, Inc.

Earnings & Dividends

News